This document provides guidance from the National Pathology Accreditation Advisory Council (NPAAC) on the use of point of care testing to support increased testing demand for SARS-CoV-2 during the coronavirus disease 2019 (COVID-19) outbreak.

This info graphic highlights the key findings from the third CDI Technical report: Monitoring the national burden of Clostridioides difficile infection in Australian public hospitals: 2016 to 2018.

This report includes analyses of the burden of CDI in Australian public hospitals in 2019.

This document corrects a cross-reference to a table in Figure 2.1: Hazard classification flow chart.

This infographic highlights the key findings from the CDI technical report: Monitoring the national burden of Clostridioides difficile infection in Australian public hospitals: 2016 to 2018. 

This document corrects a footnote in Table 2: Minimum retention times for anatomical pathology.

This document corrects a missing symbol referring to a footnote in Table 2: Minimum retention times for anatomical pathology.

The Requirements for laboratories reporting tests for the National Cervical Screening Program is a Tier 4 pathology standard.

The document below addresses concerns and answers questions regarding the First Edition of this standard.

The Requirements for supervision in the clinical governance of medical pathology laboratories is a Tier 3A pathology standard.

The Fifth Edition of the standard became effective 1 August 2019. The document below addresses common questions and provides additional guidance regarding this edition.

In July 2021, the Australian Government Department of Health released the Sixth Edition of the standard.

This report provides an overview of national prevalence of CDI in 2016, 2017 and 2018, summarising the findings of each of these Clostridioides difficile infection (CDI) data snapshot reports.